ISPOR 19TH ANNUAL EUROPEAN CONGRESS ISSUE PANEL EXPLORES ISSUE OF ADAPTIVE PATHWAYS AND PATIENT ACCESS

Published Nov 1, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held an issue panel this afternoon entitled, Adaptive Pathways and Patient Access: Pushing Payer Boundaries or Facilitating New Payment Models? The session took place at the Society’s 19th Annual European Congress in Vienna, Austria.  The issue panel was moderated by Jacoline Bouvy, PhD, Scientific Adviser, National Institute for Health and Care Excellence, London, UK. Speakers for the session included:
  • Hans-Georg Eichler, MD, MSc, Senior Medical Officer, European Medicine Agency, London, UK
  • Ad Schuurman, MSc, MBA, President of MEDEV, Zorginstituut Nederland, Diemen, The Netherlands
  • Claudine Sapede, PharmD, MSc, Global HTA and Payment Policy Lead, F. Hoffmann-La Roche Ltd, Basel, Switzerland
This panel explored the use of adaptive pathways in the development medicines. Speakers noted that adaptive pathways could help patients gain earlier access to promising treatments in areas of high unmet medical needs, but acknowledged that this approach may also have implications for access decisions at the national and regional levels that need to be explored. Jacoline Bouvy, PhD provided an overview of ADAPT SMART, the enabling platform for the coordination of Medicines Adaptive Pathways for Patients (MAPPs) activities. MAPPS seeks to foster access to beneficial treatments for the right patient groups at the earliest appropriate time in the product lifespan in a sustainable fashion. Hans-Georg Eichler, MD, MSc discussed the regulatory viewpoint on adaptive pathways, and Ad Schuurman, MSc, MBA and Claudine Sapede, PharmD, MSc provided perspectives from the payer and industry sectors, respectively. Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×